APPLICATION NUMBER:
21-398

APPROVAL LETTER
NDA 21-398

NDA APPROVAL

Allergan, Inc.
Attention: Paul Stone, Ph.D.
Director, Global Regulatory Affairs
2525 Dupont Drive
P.O. Box 19534
Irvine, CA 92623-9534

Dear Dr. Stone:

Please refer to your new drug application (NDA) dated September 17, 2001, received September 18, 2001, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for COMBIGANTM (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%.

We acknowledge receipt of your submissions dated January 30 (2), February 22, March 22, May 2, June 6, and 8, July 17, August 13, October 16, 24, and 25, 2007.

The May 2, 2007, submission constituted a complete response to our December 20, 2006, action letter.

This new drug application provides for the use of COMBIGANTM (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% for reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the enclosed labeling (text for the package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, “SPL for approved NDA 21-398.”

Submit final printed carton and container labels that are identical to the carton and immediate container labels submitted October 25, 2007, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005). Approval of this submission by FDA is not required before the labeling is used.
Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

In addition, we request that you submit one copy of the introductory promotional materials you propose to use for this product to this division.

Please submit one market package of the drug product when it is available.

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
HFD-001, Suite 5100
5515 Security Lane
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at (301) 796-0797.

Sincerely,

[See appended electronic signature page]

Wiley A. Chambers, M.D.
Acting Director
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Wiley Chambers
10/30/2007 11:28:24 AM